Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (Nasdaq: ANNX) is a biopharmaceutical company developing complement inhibitors and targeted immunotherapies for serious neuroinflammatory and classical complement-mediated diseases. The Annexon news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its C1q-focused platform.
Recent news highlights Annexon’s late-stage programs, including tanruprubart for Guillain-Barré syndrome (GBS), vonaprument for dry age-related macular degeneration with geographic atrophy (GA), and ANX1502, an oral C1s inhibitor for autoimmune conditions such as cold agglutinin disease. Investors can follow updates on the European Marketing Authorization Application for tanruprubart in GBS, plans for a Biologics License Application in the U.S., and progress of the global Phase 3 ARCHER II trial of vonaprument in GA.
News items also cover proof-of-concept work for ANX1502, financial results, public offerings of common stock and pre-funded warrants, and participation in major healthcare and investor conferences. Annexon regularly reports on its cash runway, research and development spending, and key anticipated milestones across its portfolio.
This page provides a centralized view of Annexon’s press releases and related coverage, allowing readers to track clinical data readouts, regulatory submissions, financing transactions and corporate presentations as the company advances its complement-based neuroinflammation platform.
Annexon (NASDAQ: ANNX) has granted stock options to two new non-executive employees as part of its 2022 Employment Inducement Award Plan. The equity awards, approved on May 14, 2025, include options to purchase 214,000 shares of Annexon common stock at an exercise price of $1.81 per share, matching the closing price on May 15, 2025. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Annexon (NASDAQ: ANNX) reported Q1 2025 financial results and highlighted progress across its late-stage clinical portfolio. The company's lead program tanruprubart is advancing towards BLA submission for Guillain-Barré Syndrome (GBS), with an FDA meeting scheduled for Q2 2025. The company is launching the open-label FORWARD study to provide North American and European access to tanruprubart.
Their second program, ANX007, is progressing in Phase 3 ARCHER II trial for dry AMD with geographic atrophy, with enrollment completion expected in Q3 2025 and topline data in H2 2026. The oral small molecule ANX1502 proof-of-concept trial in cold agglutinin disease is set to complete by mid-2025.
Financially, Annexon reported $263.7 million in cash and investments as of March 31, 2025, with runway into H2 2026. Q1 2025 net loss was $54.4 million ($0.37 per share), compared to $25.2 million ($0.21 per share) in Q1 2024.
Annexon (NASDAQ: ANNX) announced upcoming presentations at the 2025 Peripheral Nerve Society Annual Meeting highlighting improved outcomes with tanruprubart (formerly ANX005) for treating Guillain-Barré Syndrome (GBS). The presentations, scheduled for May 17-20, 2025 in Edinburgh, UK, will showcase comparative effectiveness data and new analyses from Phase 3 trials.
GBS is a rare autoimmune disease causing rapid weakness and potential paralysis, with no current FDA-approved treatments. Tanruprubart, a first-in-kind monoclonal antibody, targets C1q to block classical complement cascade initiation. The drug aims to halt neuroinflammation and nerve damage during acute GBS phase with a single infusion.
The presentations will include real-world evidence comparing tanruprubart to standard treatments, data linking early complement inhibition to long-term outcomes, quality of life improvements, and efficacy across a broad patient spectrum.
Annexon (NASDAQ: ANNX) announced upcoming presentations on their drug ANX007 at two major conferences: the ARVO 2025 Annual Meeting and the Retina World Congress. ANX007, a first-in-kind intravitreal Fab fragment designed to block C1q locally in the eye, has shown significant vision preservation in patients with Geographic Atrophy (GA) in dry Age-related Macular Degeneration (AMD).
The presentations will highlight ANX007's neuroprotective effects and benefits of C1q inhibition against inflammation and neuronal damage. The drug stands out as the only investigational therapy in GA demonstrating significant improvements in both best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA). The company is currently enrolling patients globally for their Phase 3 ARCHER II trial.
Annexon (ANNX) has granted a stock option inducement award to a new non-executive employee under its 2022 Employment Inducement Award Plan. The grant was approved on April 11, 2025, complying with Nasdaq Listing Rule 5635(c)(4).
The employee received options to purchase 105,000 shares of Annexon common stock at an exercise price of $1.54 per share, matching the closing price on April 15, 2025. The option has a ten-year term and vests over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Aviceda Therapeutics, a clinical-stage biotech company, has appointed Dr. Emmett T. Cunningham Jr. to its Board of Directors. Dr. Cunningham brings over 20 years of experience as a physician-scientist, healthcare entrepreneur, and investor, previously serving as Senior Managing Director at Blackstone Group.
Throughout his career, Dr. Cunningham has contributed to the FDA approval of ten therapeutics, including notable ophthalmic treatments. He previously held the position of Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a key role in developing Macugen®, the first VEGF-A inhibitor approved for specific eye conditions.
The appointment comes as Aviceda prepares to advance AVD-104 into pivotal trials for geographic atrophy, utilizing their proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform aimed at alleviating chronic, non-resolving inflammation.
Annexon (NASDAQ: ANNX) presented pivotal Phase 3 data for tanruprubart, a potential first targeted therapy for Guillain-Barré Syndrome (GBS), at the AAN 2025 Annual Meeting. The trial of 241 patients demonstrated that a single infusion of tanruprubart led to 2.4-fold higher likelihood of improved health versus placebo at Week 8.
Key findings include: patients showed 14-fold higher mobility at Week 1, twice the number of treated patients had no limitations at Week 26, and patients recovered approximately one month earlier than placebo group. The treatment reduced intensive care time by about a week. A Real World Evidence study comparing tanruprubart with standard treatments (IVIg/PE) showed superior muscle strength recovery.
GBS affects 150,000 people worldwide annually, with no FDA-approved therapies. Annexon also launched the Move GBS Forward™ education campaign to increase disease awareness among healthcare professionals.
Annexon (ANNX) is showcasing its leadership in Guillain-Barré Syndrome (GBS) research at the American Academy of Neurology Annual Meeting 2025. The company will present Phase 3 trial data for ANX005, their potential first targeted therapy for GBS, during an oral plenary session on April 8.
Key highlights include an educational symposium on GBS care and the classical complement pathway, featuring expert presenters from leading medical institutions. Additionally, Annexon is launching 'Move GBS Forward,' a disease education campaign at Booth #2133 to promote awareness of GBS's impact and encourage prompt diagnosis.
GBS affects approximately 150,000 people worldwide annually and currently has no FDA-approved therapies. ANX005, a first-in-kind monoclonal antibody, is designed to block C1q with a single infusion to stop neuroinflammation and nerve damage during acute GBS phases.
Annexon (ANNX) has granted stock options to a new non-executive employee as part of its 2022 Employment Inducement Award Plan. The equity award, approved on March 12, 2025, complies with Nasdaq Listing Rule 5635(c)(4).
The grant includes options to purchase 35,000 shares of Annexon common stock with a ten-year term and an exercise price of $2.60 per share, matching the closing price on March 14, 2025. The options vest over 4 years, with 25% vesting after the first year and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.
Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2024 financial results, highlighting progress across its late-stage clinical platform. The company maintains a strong financial position with $312 million in cash and investments as of December 31, 2024, providing runway into H2 2026.
Key developments include:
- ANX005 for Guillain-Barré Syndrome (GBS) advancing toward pre-BLA meeting in H1 2025
- Established global registration path for ANX007 as potential first vision-preserving treatment for dry AMD with GA
- Ongoing proof-of-concept trial for ANX1502, first-in-kind oral C1s inhibitor
Financial results show R&D expenses of $43.4M for Q4 2024 ($119.4M full-year), compared to $23.3M in Q4 2023 ($113.8M full-year). Net loss was $48.6M for Q4 2024 ($138.2M full-year), versus $27.9M in Q4 2023 ($134.2M full-year).